Forty-seven patients with stage II, III, or IV breast cancer undergoing autologous peripheral blood progenitor cell (PBPC) transplantation were randomized to placebo (n ‫؍‬ 13) or to one of five sequential dose cohorts of pegylated (PEG) recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) (1.0, 2.5, 5.0, 7.5, or 10.0 g/kg/day) (n ‫؍‬ 34). Blinded study drug was started on the day of transplantation and was continued until the platelet count was у100 ؋ 10 9 /l or a maximum of 21 days. PBPCs were mobilized with filgrastim (r-metHuG-CSF) and all patients received filgrastim starting on day ؉2 after transplantation. The nadir platelet count was not affected by treatment. The median time to platelet recovery was 11 and 12 days for the placebo and combined PEG-rHuMGDF groups, respectively. No trends in adverse events suggested dose-or treatment-related toxicity. Two patients withdrew from the study because of an adverse event (allergic reaction in the 7.5 g/kg group) probably related to study drug, and veno-occlusive disease (VOD) (in the 5 g/kg group) which was felt not to be related to study drug by the investigator. No patients developed neutralizing antibodies to MGDF. Day ؉21 and day ؉28 platelet counts were higher in the group receiving PEG-rHuMGDF (246 vs 148 ؋ 10 9 /l and 299 vs 145 ؋ 10 9 /l, respectively; both P Ͻ 0.05). PEG-rHuMGDF up to 10 g/kg/day was well tolerated. In this study, there was no effect of study drug on initial platelet engraftment at the doses studied. However, the efficacy of other doses is unknown. Bone Marrow Transplantation (2000) 26, 141-145.
Hematopoietic engraftment after high-dose chemotherapy and autologous progenitor cell transplant has dramatically improved over the past decade. The use of mobilized peripheral blood progenitor cells (PBPC) has been shown to significantly enhance neutrophil and platelet engraftment. [1] [2] [3] [4] [5] Currently, most patients experience initial platelet engraftment, as defined as the time to a platelet count of 20 ϫ 10 9 /l independent of transfusion support, 12 to 18 days after the infusion of mobilized PBPC. Some patients, however, experience delayed platelet engraftment that may persist for months. [6] [7] [8] [9] This thrombocytopenia may result in a delay of additional therapy required to treat their underlying malignancy. These patients may be transfusiondependent indefinitely.
Thrombopoietin, the major hormone regulating megakaryocytopoiesis, [10] [11] [12] [13] [14] [15] [16] acts through the receptor Mpl. Recombinant human megakaryocyte growth and development factor (MGDF, also known as PEG-rHuMGDF) is a polypeptide related to thrombopoietin that encompasses the receptorbinding N-terminal domain of human Mpl ligand. Preclinical studies have shown that PEG-rHuMGDF supports all stages of platelet production; 17, 18 MGDF has been shown to ameliorate carboplatin-induced thrombocytopenia in mice. 19 Two studies indicate that PEG-rHuMGDF may be active in stimulating recovery of platelet production after chemotherapy. Fanucchi et al 20 described the use of PEGrHuMGDF in patients receiving carboplatin and paclitaxel chemotherapy for lung cancer. Patients administered PEGrHuMGDF had a much higher platelet nadir than did those patients receiving placebo, and they recovered to baseline platelet counts more than 1 week earlier. Similar effects on platelet recovery were seen in a study of patients with advanced solid tumors receiving carboplatin and cyclophosphamide chemotherapy. 21 The purpose of this clinical trial was to assess the safety and efficacy of PEG-rHuMGDF in accelerating platelet recovery to transfusion-independent levels in patients with high-risk or advanced breast cancer receiving high-dose chemotherapy and autologous PBPC transplant, to assess the safety of five dose levels of PEG-rHuMGDF and to identify both the maximum tolerated dose and the clinically effective dose.
Materials and methods

Patient population
The study protocol was approved by the institutional review boards of the participating centers and all patients gave written informed consent before entry on to the trial. Adults with high-risk, stage II, stage III, or chemotherapy-responsive stage IV breast cancer were eligible for inclusion in this study. Eligibility criteria included a Karnofsky score of у80%; an absolute neutrophil count (ANC) Ͼ1.5 ϫ 10 9 /l, platelet count у100 ϫ 10 9 /l, and hemoglobin Ͼ9 g/dl. Normal cardiac, pulmonary, renal, and hepatic function were also required. Patients were not eligible if they had a history of stroke or transient ischemic attack, coronary artery angioplasty, peripheral vascular disease, deep vein thrombosis, pulmonary embolism, myocardial infarction, angina, or other serious thromboembolic disease, documented brain metastases or a previous bone marrow or PBPC transplantation.
PBPC mobilization with filgrastim and transplant preparative regimen
Mobilization of PBPCs was with filgrastim (r-metHuG-CSF) 10 g/kg/day administered subcutaneously (s.c.) with leukapheresis performed on days 5, 6 and 7 of filgrastim administration. A minimum collection of 1.0 ϫ 10 6 CD34 ϩ cells/kg was required for study entry. CD34 ϩ cell analyses were performed using a standardized flow cytometric technique at a central laboratory (Cytometry Associates, San Diego, CA, USA).
The transplant preparative regimen was STAMP I chemotherapy (cyclophosphamide 1875 mg/m 2 /day intravenously (i.v.) on days Ϫ5, Ϫ4, and Ϫ3; cisplatin 55 mg/m 2 /day continuous 24-h i.v. infusion over days Ϫ5, Ϫ4, and Ϫ3; and BCNU 600 mg/m 2 i.v. on day Ϫ2). PBPCs were infused on day 0.
Study design
Patients were randomly assigned to receive either placebo or PEG-rHuMGDF in a 1:3 ratio. The dose of PEGrHuMGDF was escalated to the next level after a minimum of four patients had been evaluated for safety according to predefined rules. Dose levels of PEG-rHuMGDF were 1.0, 2.5, 5.0, 7.5 and 10 g/kg/day administered as a s.c. injection. The blinded study drug began on the day of PBPC infusion (day 0) and was administered for 21 days, or until a platelet count of Ͼ100 ϫ 10 9 /l was achieved, whichever occurred first. All patients received daily filgrastim 10 g/kg/day s.c. beginning on day ϩ2 after transplantation until the ANC was Ͼ5 ϫ 10 9 /l for 3 days or 10 ϫ 10 9 /l for 1 day.
Supportive care
Platelet transfusions (up to two transfusions per day) were given for prophylaxis when the patient's platelet count was Ͻ10 ϫ 10 9 /l, to prevent bleeding during an invasive procedure, or to control active bleeding. Red blood cell transfusions could be given to maintain a hemoglobin level of at least 9 g/dl.
Assessment of safety
Safety was assessed in an ongoing manner during the study period. Parameters included extent of exposure to study drug and chemotherapy, adverse events, deaths, hemorrhagic and thrombotic events, clinical laboratory findings (including antibodies to MGDF) and changes in vital signs. Antibodies were assayed using a standard, solid phase ELISA.
Assessment of efficacy
The primary efficacy endpoint was the proportion of patients with a post-transplant platelet nadir у25 ϫ 10 9 /l; secondary endpoints included time to platelet recovery (as defined by the number of days from transplant to the second of 2 consecutive days of platelet count у20 ϫ 10 9 /l in the absence of prophylactic platelet transfusions), incidence, duration, and severity of thrombocytopenia, and platelet transfusion requirements.
Statistical analysis
All patients who received at least one dose of study drug were evaluable for safety. The primary analysis of efficacy was conducted on an intent-to-treat basis. Patients were included in the analysis according to their randomized dose assignment, irrespective of whether the dose of PEGrHuMGDF or placebo was modified or discontinued early. All tests of statistical significance were assessed against a two-sided alternative hypothesis using a type I error rate of 5%.
Cumulative probability distributions for the time to platelet recovery to у20 ϫ 10 9 /l were generated by the KaplanMeier method. Point estimates and 95% confidence intervals were calculated for the median recovery time. An ordered comparison among the dose groups was made using the trend version of the log-rank test. Hypothesized dose-related changes in response among the groups were further assessed using the Jonckheere-Terpstra test for the duration of severe thrombocytopenia and the number of days and units of platelet transfusions.
Results
Patients
Fifty-six patients were registered of whom 47 were randomized: 13 to receive placebo and 34 to receive PEGrHuMGDF at dosages of 1.0 (n ϭ 5), 2.5 (n ϭ 7), 5.0 (n ϭ 7), 7.5 (n ϭ 9), and 10.0 (n ϭ 6) g/kg/day. Demographics of the 47 randomized patients are shown in Table  1 . Nine patients were not randomized for the following reasons: progressive disease or severe intercurrent infection (four patients); harvest of less than 1 ϫ 10 6 CD34 ϩ cells/kg (two patients); patients deciding not to have a transplant (two patients); and an insurance company not agreeing to authorize a study involving a non-FDA approved drug (one patient).
All patients were women, median age, 44 years. Most patients had Karnofsky performance scores of 90% or 100%. All patients had received prior chemotherapy for their breast cancer (median, four cycles; range, 2-14) and 14 patients had received prior radiation therapy. The treatment groups were well balanced with respect to demographic characteristics, and the various PEG-rHuMGDF cohorts showed no appreciable differences.
PBPC mobilization with filgrastim
All patients received filgrastim (10 g/kg/day for 7 days) for PBPC mobilization. The number of CD34 ϩ cells collected from the patients assigned to receive placebo or from those assigned to receive PEG-rHuMGDF after transplantation showed no appreciable difference: patients receiving placebo had a median of 4.1 (range, 1.7-11.9) ϫ 10 
Safety
The median duration of study drug dosing was 14 days (range, 12-21) for the placebo and PEG-rHuMGDF cohorts, indicating that most patients achieved the platelet target of 100 ϫ 10 9 /l well before the 21-day maximum dosing duration. The median cumulative doses of PEGrHuMGDF for the placebo-treated and five PEGrHuMGDF-treated cohorts were 0, 0.8, 3.15, 6.0, 8.25 and 9.45 mg, respectively, reflective of the incremental dose escalation.
Most of the adverse events encountered were consistent with those typically seen in patients receiving high-dose chemotherapy, and no pattern or trend indicative of PEGrHuMGDF-related toxicity emerged. Four (31%) placeboBone Marrow Transplantation treated patients and 17 (50%) PEG-rHuMGDF-treated patients reported rash and 11 (85%) placebo-treated patients and 27 (79%) PEG-rHuMGDF-treated patients reported fever. No rash or fever was attributed to study the drug. One patient receiving PEG-rHuMGDF died on study (veno-occlusive disease (VOD)), but the investigators did not attribute the death to the study drug. One other patient (1 g/kg group) developed transient VOD. One major thrombotic event was reported: jugular vein thrombosis and catheter thrombus in one patient receiving placebo. Minor thrombotic events were reported in three patients treated with PEG-rHuMGDF: clotted central venous access catheters. No pulmonary emboli were reported. Major hemorrhagic events were reported in five patients (38%) receiving placebo and 12 patients (35%) receiving PEGrHuMGDF, consisting primarily of epistaxis (12 events) and hematuria (eight events); none was attributed to study drug.
Blood chemistries, hematology variables, vital signs, and physical findings showed no clinically significant changes.
All 47 evaluable patients had post-baseline samples for antibody testing (days 15 and 45), and 44 had subsequent samples taken during long-term observation (range, 63-250 days). All were negative for neutralizing antibodies.
Efficacy measurements
Post-transplantation nadir:
No patient in any treatment group had a platelet nadir у25 ϫ 10 9 /l, the primary endpoint. Median platelet nadirs were 8 (range, 3-17) and 5 (range, 1-9) ϫ 10 9 /l for the placebo-treated and combined PEG-rHuMGDF-treated groups, respectively.
Platelet recovery time:
Both the placebo-treated patients and all PEG-rHuMGDF-treated patients experienced rapid recovery of platelets to у20 ϫ 10 9 /l with a median of 11 days (range, 9 to 15 days) in the placebo-treated group and 12 (range, 9-43ϩ) days in the PEG-rHuMGDF-treated group (Figure 1 ). There was no difference in platelet recovery to 20 ϫ 10 9 /l between the different PEG-rHuMGDF study cohorts. 
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Other platelet variables: The median duration of thrombocytopenia Ͻ20 ϫ 10 9 /l was 7 days for both placebo-(range, 4-11) and combined PEG-rHuMGDF-treated (range, 2-40) groups. There was no difference in the number of platelet transfusion events, or in the number of days platelets were transfused between patients receiving PEGrHuMGDF and those receiving placebo (median, 3 days for both placebo-treated (range, 1-5 units) and combined PEGrHuMGDF-treated (range, 1-20 units) groups). All patients were followed for 28 days. Patients receiving PEGrHuMGDF had a higher day ϩ21 (246 vs 148 ϫ 10 9 /l, P Ͻ 0.05) and day ϩ28 (299 vs 145 ϫ 10 9 /l, P Ͻ 0.05) platelet count than the patients in the placebo group (Figure 2) .
Discussion
This study demonstrated that PEG-rHuMGDF in doses up to and including 10 g/kg/day were well tolerated after filgrastim-mobilized PBPC transplantation in patients with breast cancer. Dose-related adverse effects were not evident in the range of 1 to 10 g/kg/day. The vital signs of patients receiving PEG-rHuMGDFrHuMGDF were not different from those patients receiving placebo. No neutralizing antibodies were detected. The incidence of thrombotic events was similar to those reported in other medical settings in which indwelling large-bore central venous catheters are used routinely.
The objective of determining the maximum tolerated dose was not met. The maximum tolerated dose could not be determined because no dose-limiting toxicities and no effective dose were reached. It is possible that a dose level higher than those used in this study would have been effective, but it is unlikely as the animal data do not support this suggestion. Days since transplantation Figure 2 Kaplan-Meier estimate of cumulative probability of platelet recovery to 20 ϫ 10 9 /l. Dotted line, patients receiving placebo; solid line, all patients receiving PEG-rHuMGDF. Differences between the two groups were significant at day ϩ21 (P ϭ 0.04) and day ϩ28 (P ϭ 0.0003).
The study did not demonstrate enhancement of early platelet engraftment by PEG-rHuMGDF. Unlike filgrastim, a drug that demonstrates a biological effect within hours of administration, the peak clinical effect of PEG-rHuMGDF may not be seen for 2 weeks or more. 20 The same kinetics of response were observed in clinical studies with rHuTPO. 22 Our data suggest use of PEG-rHuMGDF after transplantation was not effective in altering the kinetics of early platelet engraftment in patients with breast cancer undergoing autologous PBPC transplantation. This was demonstrated by the prompt and consistent platelet engraftment seen in both the placebo-and PEG-rHuMGDFtreated groups (12 days after transplantation).
Platelet transfusion requirements during autologous PBPC transplantation correlate with the pretransplant platelet count. 23 A potential strategy for future trials may be to incorporate PEG-rHuMGDF before progenitor cell infusion, attempting to escalate the platelet count before PBPC transplantation and to delay the platelet nadir. This strategy might decrease the total exposure to severe thrombocytopenia during the peritransplant period.
Patients receiving PEG-rHuMGDF had a higher platelet count on day ϩ21 and day ϩ28 after PBPC transplantation. This finding is consistent with the observation that the peak biologic effect of PEG-rHuMGDF and rHuTPO occurs 10 to 17 days after administration of the last dose of PEGrHuMGDF. 22, 24 The fact that PEG-rHuMGDF-treated patients had higher platelet counts on day ϩ21 and day ϩ28 than patients who received placebo may be clinically useful for two reasons. First, radiation therapy is frequently delivered after transplantation to patients with breast cancer as part of the overall treatment strategy. The initiation of radiation therapy depends, among other things, on platelet recovery post transplant. 25, 26 Our data suggest that the use of PEG-rHuMGDF may generate higher platelet counts 3 and 4 weeks after transplantation, which may allow for the more timely administration of radiation therapy. Additionally, the use of PEG-rHuMGDF may ameliorate the number of patients experiencing problems with platelet engraftment after transplantation. These so-called 'outlier' patients are of increasing clinical importance. Haas et al 6 have described delays of platelet recovery as great as 1 to 6 years after transplantation in 12 of 145 patients receiving autologous PBPC transplantation. Reiffers et al 7 noted that 34% of patients in a series of 118 undergoing autologous PBPC transplantation for hematologic malignancies had not reached a platelet count of 50 ϫ 10 9 /l by 60 days after transplant. We have recently noted at the Cleveland Clinic Foundation that 9% of patients undergoing autologous PBPC transplantation do not reach a platelet count of 30 ϫ 10 9 /l until 6 weeks after PBPC transplantation. 23 The mechanisms responsible for delayed platelet engraftment are conjectural. Some patients may experience defective megakaryocytopoiesis. This may be a result of abnormalities in bone marrow microenvironment from previous therapy; it may be the result of qualitative or quantitative abnormalities of infused progenitor cells; or it may relate to abnormal amounts of hematopoietic cytokines after transplant. It is also possible that immune-mediated thrombocytopenia may occur after transplantation. Given that PEG-rHuMGDF enhanced the peripheral platelet count 3 and 4 weeks after transplantation, the hypothesis that some patients have decreased levels of megakaryocytestimulating cytokines, or that some platelet progenitors may be relatively insensitive to normal levels of endogenous megakaryocyte-stimulating cytokines, are attractive hypotheses. Despite the lack of clarity of the precise mechanism involved, an ability to reduce the number of patients experiencing prolonged impairment of platelet production may be of significant clinical importance. Further study of the effects of thrombopoietic cytokines such as PEGrHuMGDF is warranted in PBPC transplant populations characterized by suboptimal CD34 ϩ cell harvests or a delayed platelet recovery pattern.
